Vol 7, No 4 (2021)
Review paper
Published online: 2022-03-29

open access

Page views 4594
Article views/downloads 240
Get Citation

Connect on Social Media

Connect on Social Media

Compliance, adherence and concordance in the practice of a rheumatologist. Effectiveness of the therapeutic plan: determinants and possibilities for improvement

Ewa Mojs1
Rheumatol. Forum 2021;7(4):183-190.

Abstract

Progress in the treatment of rheumatic diseases is associated with the use of drugs focused on modifying disease mechanisms, which in turn leads to a significant improvement in health. Modern treatment is also associated with reducing the risk of disability and exclusion from important social roles. New drugs, including biological drugs, are
expensive and require compliance with the regime related to their use. The above-mentioned factors make it necessary to change attitudes and to strengthen the patient’s motivation to comply with medical recommendations. The paper presents a terminological base in the field of compliance, adherence, concordance and persistence. Moreover, factors limiting compliance with recommendations in the case of chronic diseases were indicated, as well as methods of measuring compliance and adherence, both objective and subjective. It was also shown that the pandemic situation significantly reduced the readiness of patients to comply with therapeutic recommendations, which requires a redefinition of the model of cooperation between the doctor and the patient, and numerous methods of facilitating adherence have been proposed.

Article available in PDF format

View PDF Download PDF file

References

  1. Mojs E, Brzosko M, Samborski W. Novel Approach to the Treatment in Rheumatic Diseases: From Molecule to Value for Patient. Biomed Res Int. 2018; 2018: 3495782.
  2. van Vollenhoven RF, Geborek P, Forslind K, et al. Swefot study group. Conventional combination treatment versus biological treatment in methotrexate-refractory early rheumatoid arthritis: 2 year follow-up of the randomised, non-blinded, parallel-group Swefot trial. Lancet. 2012; 379(9827): 1712–1720.
  3. Smolen JS, van der Heijde D, Machold KP, et al. Proposal for a new nomenclature of disease-modifying antirheumatic drugs. Ann Rheum Dis. 2014; 73(1): 3–5.
  4. Felson DT, Smolen JS, Wells G, et al. American College of Rheumatology, European League Against Rheumatism. American College of Rheumatology/European League against Rheumatism provisional definition of remission in rheumatoid arthritis for clinical trials. Ann Rheum Dis. 2011; 70(3): 404–413.
  5. Łazowski J, Szewczyński J. Problemy farmakoterapii i opieki farmaceutycznej u ludzi w wieku podeszłym. Farm Pol. 2003; 59(22): 1027–1037.
  6. Jasińska M, Kurczewska U, Orszulak-Michalak D. Zjawisko non-adherence w procesie opieki farmaceutycznej. Farm Pol. 2009; 65(11): 765–771.
  7. Sabate E. Adherence to long-term therapies: evidence for action. World Health Organization, Geneva 2003. http://www. who.int/chp/knowledge/publications/adherence_report/en/index.html.
  8. Feliz-Giemza A. Strategia leczenia chorych na reumatoidalne zapalenie stawów z uwzględnieniem obecności czynników „złej prognozy”. Forum Reumatol. 2017; 2(3): 57–64.
  9. Smolen JS, Landewé R, Bijlsma J, et al. EULAR recommendations for the management of rheumatoid arthritis with synthetic and biological disease-modifying antirheumatic drugs: 2016 update. Ann Rheum Dis. 2017; 76(6): 960–977.
  10. Zapała J. Compliance, adherence i concordance w relacji między lekarzem a pacjentem jako zintegrowany model komunikacji 2018, 22 (3): 102–106. Psychoonkologia. 2018; 22(3): 102–106.
  11. Bell JS, Airaksinen MS, Lyles A, et al. Concordance is not synonymous with compliance or adherence. Br J Clin Pharmacol. 2007; 64(5): 710–1; author reply 711.
  12. Jankowska-Polańska B, Uchmanowicz J. Stosowanie się do zaleceń terapeutycznych w niewydolności serca. Choroby Serca i Naczyń. 2016; 13(3): 227–234.
  13. Dworakowska A, Aniszewska A, Kozłowska-Wojciechowska M. Pharmacist opportunities to support medicationadherence. Farmacja Pol. 2018; 74(3): 164–169.
  14. Vrijens B, De Geest S, Hughes DA, et al. ABC Project Team. A new taxonomy for describing and defining adherence to medications. Br J Clin Pharmacol. 2012; 73(5): 691–705.
  15. Lennecke K. Przestrzeganie zaleceń terapeutycznych. In: Wiela-Hojeńska A. ed. Farmacja kliniczna. MedPharm, Wrocław 2014.
  16. Ho PM, Spertus JA, Masoudi FA, et al. Impact of medication therapy discontinuation on mortality after myocardial infarction. Arch Intern Med. 2006; 166(17): 1842–1847.
  17. Perreault S, Ellia L, Dragomir A, et al. Effect of statin adherence on cerebrovascular disease in primary prevention. Am J Med. 2009; 122(7): 647–655.
  18. Dułacz K, Borowczyk M, Leszczyński P. Wytrwałość w przestrzeganiu zaleceń lekarskich u pacjentów z reumatoidalnym zapaleniem stawów leczonych metotreksatem. Forum Reumatol. 2020; 6(4): 147–154.
  19. Simpson SH, Eurich DT, Majumdar SR, et al. A meta-analysis of the association between adherence to drug therapy and mortality. BMJ. 2006; 333(7557): 15.
  20. Thompson AM, Dewar J, Fahey T, et al. 2007 Breast Cancer Symposium. In Association of poor adherence to prescribed tamoxifen with risk of death from breast cancer; 2007. San Francisco, Abstract No 130.
  21. Fundacja Na Rzecz Wspierania Rozwoju Polskiej Farmacji i Medycyny: Polskiego pacjenta portret własny – raport o przestrzeganiu zaleceń terapeutycznych przez polskich pacjentów. Warszawa 2010.
  22. Ernst FR, Grizzle AJ. Drug-related morbidity and mortality: updating the cost-of-illness model. J Am Pharm Assoc (Wash). 2001; 41(2): 192–199.
  23. Pylak Piwko O, Nieradko Iwanicka B. How patient’s adherence could be improved – a short eview. Journal of Education, Health and Sport. 2017; 7(8): 1610–1627.
  24. Kuypers D, Peeters PC, Sennesael JJ. Improved adherence to tacrolimus once-daily formulation in renal recipients. Transplant. J. 2013; 95: 333–340.
  25. Gorostowicz A, Wasik A, Krupa A, et al. Przestrzeganie zaleceń terapeutycznych w grupie pacjentów z zaburzeniami depresyjnymi oraz lękowymi. Psychiatria i Psychologia Kliniczna. 2019; 19(2): 177–187.
  26. Briesacher BA, Andrade SE, Fouayzi H, et al. Comparison of drug adherence rates among patients with seven different medical conditions. Pharmacotherapy. 2008; 28(4): 437–443.
  27. Horne R. Compliance, adherence, and concordance: implications for asthma treatment. Chest. 2006; 130(1 Suppl): 65S–72S.
  28. Urquhart J. The odds of the three nons when an aptly prescribed medicine isn't working: non-compliance, non-absorption, non-response. Br J Clin Pharmacol. 2002; 54(2): 212–220.
  29. Krajewska-Kułak, E., Łukaszuk, C., & Kułak, W. Wpływ właściwej komunikacji zespół terapeutyczny-pacjent na zapobieganie nieprzestrzeganiu zaleceń terapeutycznych. https://www.google.com/url?sa=t&rct=j&q=&esrc=s&source=web&cd=&ved=2ahUKEwiPg-iWtpD2AhWGAxAIHSgNAFkQFnoECAIQAQ&url=https%3A%2F%2Fppm.umb.edu.pl%2Fdocstore%2Fdownload%2FUMBa43627e65d1e43e198266c72415b4714%2F0000064316-wcag.pdf&usg=AOvVaw2EE5w71206Ah-83k71gnVX.
  30. Rupiński R. Ból – jak leczyć go skutecznie i bezpiecznie w dobie COVID-19? MiŻ Internet. 16 December 2020; 7(3–4): 5–12. https://www.journalsmededu.pl/index.php/medycyna_i_zycie/article/view/1114.
  31. Kretchy IA, Asiedu-Danso M, Kretchy JP. Medication management and adherence during the COVID-19 pandemic: Perspectives and experiences from low-and middle-income countries. Res Social Adm Pharm. 2021; 17(1): 2023–2026.
  32. Samborski W, Brzosko M. Reumatologia praktyczna. Wolters Kluwer, Kraków 2011.
  33. Krzyżanowska M, Moryson W, Prokop E, et al. Is compliance with lifestyle modifications dependent on sociodemographic factors and awareness of HF symptoms? Impact of lifestyle changes on HF patients’ wellbeing. Journal of Medical Science. 2017; 86(2): 154–162.